The Next Step in Smoking Prevention: the Reduction of Tobacco Retail Outlets, a Comprehensive Policy Evaluation
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Sep 21, 2022
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Problem description: Tobacco use is the primary cause of several cancers; among them lung cancer, which is the leading preventable cause of death in the Netherlands. Yet, tobacco use remains high in the Netherlands, with an adult smoking prevalence of 20%, which is even higher in groups with a lower socioeconomic position. Therefore, reducing the smoking prevalence in all groups in society is one of the three priorities in the Dutch National Prevention Agreement. This Agreement was made with the Dutch government and more than 70 societal organizations, including the Dutch Cancer Society. It...
Gender
ALL
Eligibility criteria
- • Group non-smoking adolescents
- Inclusion Criteria:
- • Dutch-speaking
- • aged 12 to 17 years old at enrollment
- Exclusion Criteria:
- • they have smoked (part of) a cigarette at least once a month during the last six months
- • not providing informed consent to participate
- • Smoking adults
- Inclusion Criteria:
- • Dutch-speaking
- • smoking at least monthly at enrollment
- • having smoked at least 100 cigarettes in their lifetime
- Exclusion Criteria:
- • not providing informed consent to participate
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, , Netherlands
Patients applied
Trial Officials
Gera E Nagelhout, PhD
Principal Investigator
Maastricht University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials